GRI Bio (GRI) Schedule 13G/A: 90,475 shares represent 5.9% stake

GRI Bio, Inc. has filed an Amendment No. 2 to a Schedule 13G/A, reporting that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC beneficially own 90,475 shares of common stock, representing a 5.9% stake. These shares are issuable upon the exercise of a warrant held by Intracoastal, based on 1,445,029 shares outstanding as of January 29, 2026. The filing notes two additional warrants with 4.99% blocker provisions, which are excluded from this reported percentage.

Original reporting
Published May 14, 2026, 4:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 14, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GRI
Bullish
medium confidence
Mentioned
$GRI
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$GRIBullishMed
01

Why it matters

This ownership change could signal positive sentiment, possibly leading to short-term price appreciation.

02

Market read

While relevant within biotech investment circles, the overall market impact remains limited due to the company's size and sector.

03

What to watch

Potential dilution effects from warrants and options not exercised yet could offset ownership gains.

Relevance 6/10Timing: short-term (within 1-2 weeks)

Background

GRI Bio filed an amended Schedule 13G/A revealing increased ownership by institutional investors, indicating confidence.

Company-level read

Ticker impact

$GRIBullishMedium confidence
Context

The filing indicates a significant passive stake increase by notable investors, which could influence market perception.

Expected impact

Moderate upward price movement expected over the short to medium term.

Evidence & confidence

Ownership changes by institutional investors often signal confidence, but the lack of recent price action data limits certainty.

Market effects

Potential positive sentiment in biotech and life sciences sectors due to increased investor confidence.

Limited regional impact; primarily relevant to US markets where GRI operates.

Minimal; GRI is a niche biotech firm with limited global influence.

Counterpoint

The ownership increase may be a defensive move or a sign of insider accumulation without broader positive implications.

Key entities

  • Mitchell P. Kopin

    Beneficial owner of shares.

  • Daniel B. Asher

    Beneficial owner of shares.

  • Intracoastal Capital LLC

    Holder of warrants and shares.

Related articles

$GRIMedAI 9/10

GRI Bio 3Q 2026: EPS ($0.69) — 10-Q Summary

GRI Bio reported no revenue and a narrowed net loss for 3Q 2026, citing reduced spending on GRI-0621 development. The Phase 2a trial met endpoints with no serious adverse events. FDA granted Orphan Drug Designation for GRI-0621. The company plans to file an IND application for GRI-0803 in 2027.

$PMIMed

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

$GRIMed

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRI Bio (NASDAQ: GRI) said the FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis (IPF). The company noted the designation may provide up to seven years of U.S. market exclusivity after approval, plus potential tax credits and fee waivers. GRI-0621 is an oral RARβ/γ agonist; a Phase 2a trial in 35 patients met endpoints, per the company.

$NVDAMed

Nvidia's $332 Billion AI Cloud Bet Has a Second Act

Nvidia (NVDA) announced up to $32B in commitments for neocloud agreements, aiding cloud providers in expanding AI computing power. Revenue will come from hardware sales and potential revenue sharing. Key milestones include securing funding and operational capacity, with $6B in fiscal 2028, $7B in 2029, and $8B from 2032 onwards.

$KNSAMed

Top pharma stock to watch: TD Cowen’s pick

TD Cowen identifies Kiniksa Pharmaceuticals (KNSA) as a top pick in the pharma sector, citing strong commercial momentum for Arcalyst and potential value from pipeline candidates. The firm set a $115 price target, noting underpenetrated markets and conservative revenue growth projections. KPL-387, a wholly owned drug, could add $6 to earnings per share by 2027.